News
The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results